UAE Becomes Second Country to Approve Guselkumab for Crohn's Disease Treatment
This move significantly expands treatment options for patients with chronic inflammatory bowel disorders, particularly those unresponsive to current therapies. Guselkumab has shown strong clinical results in managing symptoms and improving outcomes for individuals living with inflammatory bowel disease.
Dr. Fatima Al Kaabi, Director-General of the EDE, said the decision reflects the UAE's proactive healthcare strategy. 'With new indications for Guselkumab being approved, we see the impact of the UAE's forward-looking policies in accelerating access to innovative therapies and enhancing pharmaceutical security,'
she stated.
The approval stems from a rigorous evaluation of global clinical data, confirming Guselkumab's potential in tackling treatment-resistant Crohn's cases. It also aligns with the UAE's broader goal of ensuring rapid access to cutting-edge medical solutions through precision-driven regulatory processes and global partnerships. 'Our fast-track framework, supported by advanced technologies and strong collaboration with international pharmaceutical companies, has helped streamline reviews without compromising safety or efficacy,'
Al Kaabi added.
This milestone further underscores the UAE's role as a regional and global leader in healthcare innovation. The EDE's commitment to modernising regulatory systems ensures that patients across the country have timely access to the latest treatments, reinforcing the nation's position as a trusted hub for advanced medical solutions.
News Source: Emirates News Agency
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Hi Dubai
10-07-2025
- Hi Dubai
Dubai Culture and Dubai Health Sign MoU to Integrate Art into Healthcare Environments
Dubai Culture and Dubai Health have signed a strategic memorandum of understanding to embed art into healthcare settings across the emirate, aiming to enhance patient wellbeing and strengthen the role of creativity in public health. The agreement was witnessed by H.H. Sheikha Latifa bint Mohammed bin Rashid Al Maktoum, Chairperson of Dubai Culture, and signed by Hala Badri, Director General of Dubai Culture, and Dr. Amer Sharif, CEO of Dubai Health. The MoU activates the 'Art for Good – Health Pillar' initiative, which will incorporate art and human-centred design into hospitals and healthcare facilities. The goal is to create emotionally supportive environments that foster healing and reflect Dubai's vision for a high quality of life. The initiative supports the Dubai Quality of Life Strategy 2033 and the Dubai Social Agenda 33, which focus on advancing public health, family cohesion, and social wellbeing. It also opens new avenues for artists and creatives to contribute to healthcare-focused projects. Hala Badri emphasised the value of integrating arts into everyday life, noting that creative expression plays a vital role in both emotional resilience and social cohesion. 'Art becomes a vital tool of emotional support and recovery, creating healing environments that care for both body and spirit,' she said. Dr. Amer Sharif described the initiative as a model for inter-agency collaboration that places people at the centre of healthcare innovation. 'Holistic care includes mental and emotional wellbeing,' he said. 'This partnership reflects our commitment to enriching the healing journey through culture.' Both entities will work jointly to implement, evaluate, and expand the initiative, reaffirming Dubai's position as a forward-thinking city where creativity and wellbeing go hand in hand. News Source: Emirates News Agency
Dubai Eye
08-07-2025
- Dubai Eye
UAE first to approve oral therapy for rare autoimmune disorder
The UAE has become the first country in the world to approve an oral therapy for a rare autoimmune disorder. The newly authorised drug, Rilzabrutinib, targets Immune Thrombocytopenia - a condition that affects just a few individuals per 100,000 worldwide. Developed by global pharmaceutical company Sanofi, Rilzabrutinib is the first oral Bruton's tyrosine kinase inhibitor to be approved for this condition. The treatment works by restoring immune system balance and increasing platelet counts, offering patients faster relief and improved quality of life. Clinical studies have demonstrated promising outcomes, with patients reporting substantial improvement in health indicators. Dr. Fatima Al Kaabi, Director-General of the Emirates Drug Establishment, says the approval reflects the UAE's commitment to pioneering advanced therapies and strengthening its role as a regional leader in pharmaceutical innovation. #WamNews — WAM English (@WAMNEWS_ENG) July 8, 2025
TAG 91.1
08-07-2025
- TAG 91.1
UAE first to approve oral therapy for rare autoimmune disorder
The UAE has become the first country in the world to approve an oral therapy for a rare autoimmune disorder. The newly authorised drug, Rilzabrutinib, targets Immune Thrombocytopenia - a condition that affects just a few individuals per 100,000 worldwide. Developed by global pharmaceutical company Sanofi, Rilzabrutinib is the first oral Bruton's tyrosine kinase inhibitor to be approved for this condition. The treatment works by restoring immune system balance and increasing platelet counts, offering patients faster relief and improved quality of life. Clinical studies have demonstrated promising outcomes, with patients reporting substantial improvement in health indicators. Dr. Fatima Al Kaabi, Director-General of the Emirates Drug Establishment, says the approval reflects the UAE's commitment to pioneering advanced therapies and strengthening its role as a regional leader in pharmaceutical innovation. Emirates Drug Establishment approves world's first oral therapy for immune thrombocytopenia #WamNews — WAM English (@WAMNEWS_ENG) July 8, 2025
